Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 881.35, up by 2.40 points or 0.27% from its previous closing of Rs. 878.95 on the BSE.

The scrip opened at Rs. 885.50 and has touched a high and low of Rs. 889.00 and Rs. 876.00 respectively. So far 86,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 593.95 on 05-Jun-2014.

Last one week high and low of the scrip stood at Rs. 1003.65 and Rs. 869.50 respectively. The current market cap of the company is Rs. 2,12,289.00 crore.

The promoters holding in the company stood at 63.56% while Institutions and Non-Institutions held 24.52% and 11.91% respectively.

Sun Pharmaceutical Industries has entered into a distribution services agreement with AstraZeneca Pharma India (AZPIL) for AstraZeneca’s brand ‘Axcer’, a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS).

AZPIL already has a brand under the trademark ‘Brilinta’, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012.

Sun Pharma will be promoting and distributing ‘Axcer’ brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy.